Form 8-K PERRIGO Co plc For: Apr 28
- Nasdaq retreats as rate hike fears cool stock rally
- Disney (DIS) Stock Gains on Disney+ Beat and Raised Prices, Earns Upgrade to Buy
- Sonos Plunges as Weak Demand Prompts Outlook Cut, Analyst Seeks to See More Stabilization in Business
- AppLovin (APP) Shares Drop After Earnings Miss, Analyst Sees Growing Risks
- Bumble (BMBL) Falls on Slashed Revenue Guidance, Q2 Results Seen as 'Solid'
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
FOR IMMEDIATE RELEASE
PERRIGO ANNOUNCES EXPECTED TRANSACTION CLOSE DATE OF HRA PHARMA
Dublin, Ireland April 28, 2022 Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the closing date of the previously announced acquisition of Héra SAS (HRA or HRA Pharma) is expected to occur on April 29, 2022, subject to the satisfaction or waiver of the remaining closing conditions set forth in the securities sale agreement.
Perrigo Company plc (NYSE: PRGO) is a leading provider of Quality, Affordable Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Led by its consumer self-care strategy, Perrigo is the largest store brand OTC player in the U.S. in the categories in which it competes through more than 9,000 SKUs under customer own brand labels. Additionally, Perrigo is a Top 10 OTC company by revenue in Europe, where it markets more than 200 branded OTC products throughout 28 countries. Visit Perrigo online at www.perrigo.com.
Certain statements in this press release are forward-looking statements. These statements relate to future events or the Companys future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as may, will, could, would, should, expect, forecast, plan, anticipate, intend, believe, estimate, predict, potential or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Companys control, including: the effect of the coronavirus (COVID-19) pandemic and its variants and the associated supply chain impacts on the Companys business; general economic, credit, and market conditions; the impact of the war in Ukraine, including the effects of economic and political sanctions imposed by the United States, European Union, and other countries related thereto, and/or the outbreak or escalation of conflict in other regions where we do business; future impairment charges; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; resolution of uncertain tax positions, including the Companys appeal of the draft and final Notices of Proposed Assessment (NOPAs) issued by the U.S. Internal Revenue Service and the impact that an adverse result in any such proceedings would have on operating results, cash flows, and liquidity; pending and potential third-party claims and litigation, including litigation relating to the Companys restatement of previously-filed financial information and litigation relating to
uncertain tax positions, including the NOPAs; potential impacts of ongoing or future government investigations and regulatory initiatives; potential costs and reputational impact of product recalls or sales halts; the impact of tax reform legislation and healthcare policy; the timing, amount and cost of any share repurchases; fluctuations in currency exchange rates and interest rates; the Companys ability to achieve the benefits expected from the sale of its Rx business and the risk that potential costs or liabilities incurred or retained in connection with that transaction may exceed the Companys estimates or adversely affect the Companys business or operations; the consummation and success of the proposed acquisition of HRA Pharma and the ability to achieve the expected benefits thereof, including the risk that the parties fail to fulfill the conditions to closing on the expected timeframe or at all, the occurrence of any other event, change or circumstance that could delay the transaction or result in the termination of the securities sale agreement or the risks that the Companys synergy estimates are inaccurate or that the Company faces higher than anticipated integration or other costs in connection with the proposed acquisition; the consummation and success of other announced and unannounced acquisitions or dispositions, and the Companys ability to realize the desired benefits thereof; and the Companys ability to execute and achieve the desired benefits of announced cost-reduction efforts and strategic and other initiatives. An adverse result with respect to the Companys appeal of any material outstanding tax assessments or pending litigation, including securities or drug pricing matters, could ultimately require the use of corporate assets to pay such assessments, damages from third-party claims, and related interest and/or penalties, and any such use of corporate assets would limit the assets available for other corporate purposes. These and other important factors, including those discussed under Risk Factors in the Companys Form 10-K for the year ended December 31, 2021, as well as the Companys subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Bradley Joseph, Vice President, Global Investor Relations & Corporate Communications, (269) 686-3373, E-mail: [email protected]
Nicholas Gallagher, Manager, Global Investor Relations & Corporate Communications, (269) 686-3238, E-mail: [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Perrigo (PRGO) Reports In-Line Q2 EPS
- ECN Capital Reports US$0.09 in Adjusted Net Income per Common Share in Q2-2022
- COPT Declares 99th Consecutive Common Dividend
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!